📊 ABBV Key Takeaways
Is AbbVie Inc. (ABBV) a Good Investment?
AbbVie demonstrates strong operational efficiency with 24.6% operating margins and robust free cash flow generation of $17.8B, but faces significant financial constraints from negative stockholders' equity (-$3.3B) and high debt levels ($64.5B) that limit financial flexibility. Revenue growth stagnation (0.0% YoY) combined with deteriorating liquidity ratios (0.67x current ratio) raises concerns about sustainability despite solid cash generation and profitability.
AbbVie shows strong fundamental cash generation, with $17.82B of free cash flow and a 29.1% FCF margin, which supports resilience despite modest earnings growth. However, revenue is flat, diluted EPS declined, liquidity is weak, and the balance sheet remains highly levered with negative equity, limiting the quality of the growth profile. Overall, the business is fundamentally solid but not clean enough to justify an aggressive rating based on current operating and balance-sheet trends alone.
Why Buy AbbVie Inc. Stock? ABBV Key Strengths
- Exceptional operating cash flow of $19.0B with 29.1% FCF margin demonstrates strong underlying business quality
- High operating margin of 24.6% and gross margin of 19.7% indicate pricing power and operational efficiency in pharmaceutical sector
- Robust interest coverage ratio of 5.2x suggests adequate debt servicing capability despite leverage concerns
- Strong free cash flow generation with $19.03B operating cash flow and $17.82B free cash flow
- Healthy operating profitability, including a 24.6% operating margin and 5.2x interest coverage
- Large-scale asset base and consistent net income generation despite sector pressures
ABBV Stock Risks: AbbVie Inc. Investment Risks
- Negative stockholders' equity of -$3.3B indicates balance sheet deterioration and potential shareholder value destruction from previous capital allocation decisions
- Weak liquidity position with current ratio of 0.67x and quick ratio of 0.56x creates refinancing and operational flexibility risks
- Stagnant revenue growth (0.0% YoY) combined with flat EPS growth (-1.3% YoY) suggests pipeline weakness or maturation of product portfolio in competitive pharmaceutical market
- Flat revenue growth suggests limited near-term expansion and raises dependence on cost control or portfolio mix
- Negative stockholders equity and $64.50B of long-term debt indicate elevated balance-sheet risk
- Weak liquidity metrics, including a 0.67x current ratio and 0.56x quick ratio, reduce financial flexibility
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Stockholders' equity recovery and debt reduction from FCF generation
- Working capital trends and current ratio improvement given liquidity concerns
- Revenue growth and diluted EPS trend
- Free cash flow durability relative to debt load and liquidity
AbbVie Inc. (ABBV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 29.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
ABBV Profit Margin, ROE & Profitability Analysis
ABBV vs Healthcare Sector: How AbbVie Inc. Compares
How AbbVie Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AbbVie Inc. Stock Overvalued? ABBV Valuation Analysis 2026
Based on fundamental analysis, AbbVie Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AbbVie Inc. Balance Sheet: ABBV Debt, Cash & Liquidity
ABBV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AbbVie Inc.'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $2.72 reflects profitable operations.
ABBV Revenue Growth, EPS Growth & YoY Performance
ABBV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.5B | $186.0M | $0.10 |
| Q2 2025 | $14.5B | $938.0M | $0.52 |
| Q1 2025 | $12.3B | $1.3B | $0.72 |
| Q3 2024 | $13.9B | $1.6B | $0.88 |
| Q2 2024 | $13.9B | $1.4B | $0.77 |
| Q1 2024 | $12.2B | $239.0M | $0.13 |
| Q3 2023 | $13.9B | $1.8B | $1.00 |
| Q2 2023 | $13.9B | $924.0M | $0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AbbVie Inc. Dividends, Buybacks & Capital Allocation
ABBV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AbbVie Inc. (CIK: 0001551152)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABBV
What is the AI rating for ABBV?
AbbVie Inc. (ABBV) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABBV's key strengths?
Claude: Exceptional operating cash flow of $19.0B with 29.1% FCF margin demonstrates strong underlying business quality. High operating margin of 24.6% and gross margin of 19.7% indicate pricing power and operational efficiency in pharmaceutical sector. ChatGPT: Strong free cash flow generation with $19.03B operating cash flow and $17.82B free cash flow. Healthy operating profitability, including a 24.6% operating margin and 5.2x interest coverage.
What are the risks of investing in ABBV?
Claude: Negative stockholders' equity of -$3.3B indicates balance sheet deterioration and potential shareholder value destruction from previous capital allocation decisions. Weak liquidity position with current ratio of 0.67x and quick ratio of 0.56x creates refinancing and operational flexibility risks. ChatGPT: Flat revenue growth suggests limited near-term expansion and raises dependence on cost control or portfolio mix. Negative stockholders equity and $64.50B of long-term debt indicate elevated balance-sheet risk.
What is ABBV's revenue and growth?
AbbVie Inc. reported revenue of $61.2B.
Does ABBV pay dividends?
AbbVie Inc. pays dividends, with $11,657.0M distributed to shareholders in the trailing twelve months.
Where can I find ABBV SEC filings?
Official SEC filings for AbbVie Inc. (CIK: 0001551152) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABBV's EPS?
AbbVie Inc. has a diluted EPS of $2.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABBV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AbbVie Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ABBV stock overvalued or undervalued?
Valuation metrics for ABBV: ROE of N/A (sector avg: 15%), net margin of 6.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ABBV stock in 2026?
Our dual AI analysis gives AbbVie Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABBV's free cash flow?
AbbVie Inc.'s operating cash flow is $19.0B, with capital expenditures of $1.2B. FCF margin is 29.1%.
How does ABBV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.67 (avg: 2).